| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b55c349b43c3ecba4977fd52cc8f8c67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0cfda08d50d1857d9282cec4df496c2d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-045 |
| filingDate |
1998-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2006-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc55da37cb2d0a6fda6bd74a093f6804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83f8cfae412cb1e7019b6bd6498a7607
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_def26da414bd1d67cc3dd76e38882de5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_379f419de0d020ff52a13bcb1cbf2fa5 |
| publicationDate |
2006-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2255447-C |
| titleOfInvention |
Percutaneous absorption type preparation |
| abstract |
A percutaneous absorption type preparation comprising a support and a plaster layer laminated thereon, which comprises tulobuterol in a proportion of not less than 5 wt% in a dissolution state and an adhesive. The preparation of the present invention retains the active ingredient, tulobuterol, at a high concentration in a complete dissolution state in the plaster layer. Therefore, it is free of time-course changes in drug releasing property and adhesive property caused by precipitation of drug crystals with the lapse of time. The inventive preparation is superior in percutaneous absorption of the drug, particularly percutaneous absorption rate at the initial stage of the administration; shows superior duration of efficacy by maintaining effective blood concentration for a long time; and is associated with less changes with the lapse of time in adhesive property such as adhesion to the skin. |
| priorityDate |
1997-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |